Sulforaphane protection against the development of doxorubicin‐induced chronic heart failure is associated with Nrf2 Upregulation
Open Access
- 21 June 2017
- journal article
- research article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 35 (5)
Abstract
Summary: Background: Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose‐dependent cardiotoxicity and even progresses to chronic heart failure (CHF).Objective: This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX‐induced CHF.Methods: Male Sprague‐Dawley rats which received treatment for 6 weeks were divided into four groups (n=30 per group): control, SFN, DOX and DOX plus SFN group.Results: Results revealed that DOX induced progressive cardiac damage as indicated by increased cardiac injury markers, cardiac inflammation, fibrosis and oxidative stress. SFN significantly prevented DOX‐induced progressive cardiac dysfunction between 2‐6 weeks and prevented DOX‐induced cardiac function deterioration. Furthermore, it significantly decreased ejection fraction and increased the expression of brain natriuretic peptide. SFN also almost completely prevented DOX‐induced cardiac oxidative stress, inflammation and fibrosis. SFN upregulated NF‐E2‐related factor 2 (Nrf2) expression and transcription activity, which was reflected by the increased mRNA expression of Nrf2 and its downstream genes. Furthermore, in cultured H9c2 cardiomyocytes, the protective effect of SFN against DOX‐induced fibrotic and inflammatory responses was abolished by Nrf2 silencing.Conclusion: We arrived at the conclusion that DOX‐induced CHF can be prevented by SFN through the upregulation of Nrf2 expression and transcriptional function.Keywords
Funding Information
- National Natural Science Foundation of China (81300186, 81301035)
This publication has 38 references indexed in Scilit:
- Sulforaphane prevention of diabetes-induced aortic damage was associated with the up-regulation of Nrf2 and its down-stream antioxidantsNutrition & Metabolism, 2012
- Sulforaphane Potentiates RNA Damage Induced by Different XenobioticsPLOS ONE, 2012
- Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathyBiomedicine & Pharmacotherapy, 2012
- NADPH oxidase-dependent oxidative stress in the failing heart: From pathogenic roles to therapeutic approachFree Radical Biology and Medicine, 2012
- Prevention of Diabetic Nephropathy by Sulforaphane: Possible Role of Nrf2 Upregulation and ActivationOxidative Medicine and Cellular Longevity, 2012
- Nrf2 Activators as Attractive Therapeutics for Diabetic NephropathyDiabetes, 2011
- Cruciferous Vegetable Phytochemical Sulforaphane Affects Phase II Enzyme Expression and Activity in Rat Cardiomyocytes through Modulation of Akt Signaling PathwayJournal of Food Science, 2011
- Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicityCell Death & Disease, 2011
- The influence of sulforaphane on vascular health and its relevance to nutritional approaches to prevent cardiovascular diseaseEPMA Journal, 2011
- Baroreflex Sensitivity and Oxidative Stress in Adriamycin-Induced Heart FailureHypertension, 2001